检索结果-南通市图书馆

Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2013年第36期19卷 6062-6068页

作者： Sang-Won kim Do Hoon Lim Yong Chan Ahn Won Seog kim seok jin kim Young Hyeh Ko Kyoung-Mee kim Department of Radiation Oncology Samsung Medical Center Sungkyunkwan University School of Medicine Division of Hematology and Oncology Department of Medicine Samsung Medical CenterSungkyunkwan University School of Medicine Department of Pathology Samsung Medical Center Sungkyunkwan University School of Medicine

AIM:To evaluate the clinical outcomes of radiation therapy(RT)for early-stage gastric mucosa-associated lymphoid tissue lymphoma(MALToma).METHODS:The records of 64 patients treated between 1998 and 2011 were analyzed *** Helicobacter pylori(***)-positive patients(n=31),chemotherapy or *** eradication therapy was the initial *** patients with failure after *** eradication,RT was *** *** patients(n=33),chemotherapy or RT was the first-line *** median RT dose was *** target volume included the entire stomach andthe perigastric lymph node ***:All of the patients completed RT without interruption and showed complete remission on endoscopic biopsy after *** a median follow-up period of 39 mo,the 5-year local control rate was 89%.Salvage therapy was successful in all relapsed *** malignancies developed in three *** 5-year overall survival rate was 94%.No patient presented symptoms of moderate-to-severe treatmentrelated toxicities during or after ***:Radiotherapy results in favorable clinical outcomes in patients with early-stage gastric MALToma who experience failure of *** eradication therapy and those who are *** negative.

关键词： Gastric mucosa-associated lymphoid tissue lymphoma Radiation therapy Treatment response

Understanding of the capacity Contribution of carbon in phosphorus-carbon composites for high-performance anodes in lithium ion batteries

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Nano Research 2017年第4期10卷 1268-1281页

作者： Jiantie Xu In-Yup Jeon Jianmin Ma Yuhai Dou seok-jin kim Jeong-Min Seo Huakun Liu Shixue Dou Jong-Beom Baek Liming Dai Institute for Superconducting and Electronic Materials University of Wollongong Wollongong NSW 2522 Austrafia School of Energy and Chemical Engineering/Low-Dimensional Carbon Materials Center Ulsan National Institute of Science and Technology (UNIST) UNIST-gi150 Ulsan 689-897 Republic of Korea Department of Macromolecular Science and Engineering Case Western Reserve University Cleveland OH 44106 USA

Phosphorus has recently received extensive attention as a promising anode for lithium ion batteries （LIBs） due to its high theoretical capacity of 2,596 mAh·g^-1. To develop high-performance phosphorus anodes for LIBs, carbon materials have been hybridized with phosphorus （P-C） to improve dispersion and con- ductivity. However, the specific capacity, rate capability, and cycling stability of P-C anodes are still less than satisfactory for practical applications. Furthermore, the exact effects of the carbon support on the electrochemical performance of the P-C anodes are not fully understood. Herein, a series of xP-yC anode materials for LIBs were prepared by a simple and efficient ball-milling method. 6P-4C and 3P-7C were found to be optimum mass ratios of x/y, and delivered initial discharge capacities of 1,803.5 and 1,585.3-mAh·g^-1, respectively, at 0.1 C in the voltage range 0.02-2 V, with an initial capacity retention of 68.3% over 200 cycles （more than 4 months cycling life） and 40.8% over 450 cycles. The excellent electrochemical performance of the 6P-4C and 3P-7C samples was attributed to a synergistic effect from both the adsorbed P and carbon.

关键词： phosphorus carbon synergistic effect anode lithium ion batteries

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma:amulticenter,retrospective analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2021年第3期41卷 275-278页

作者： Jun Ho Yi seok jin kim Dok Hyun Yoon Cheolwon Suh Myung Hee Chang Deok Hwan Yang Jae-Cheol Jo Shin Young Hyun Hyeon-seok Eom Jeong-Ok Lee Ji Hyun Kwon Sang Hoon Han Seung-Shin Lee Jae-Yong Kwak Se Hyung kim Dae Sik kim Ji Hyun Lee Sung Yong Oh Hun Mo Ryoo Hyo Jung kim Won Seog kim Division of Hematology-Oncology Department of MedicineChung-Ang UniversityDongjak-guSeoul 06973Korea Division of Hematology and Oncology Department of MedicineSamsung Medical Center Sungkyunkwan University School of MedicineGangnam-guSeoul 06351Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guSeoul 05505Korea National Health Insurance Corporation Ilsan Hospital Ilsandong-guGoyang 10444Korea Department of Hemato-Oncology Chonnam National University Hwasun HospitalChonnam National University Medical SchoolHwasunGwangju 58128Korea Department of Hematology and Oncology Ulsan University HospitalUniversity of Ulsan College of MedicineDong-guUlsan 44033Korea Department of Internal Medicine Yonsei University Wonju College of MedicineGangwon-DoWonju 26426Korea Department of Internal Medicine National Cancer CenterGoyang-si Gyeonggi-doGoyang 10408Korea Department of Internal Medicine Seoul National University Bundang HospitalBundang-guSeongnam 13620Korea Department of Internal Medicine ChungBuk National University HospitalChungbukCheongju 28644Korea Department of Internal Medicine Jeju National University HospitalJeju National University School of MedicineJeju 63241Korea Department of Hematology-Oncology Wonkwang University HospitalIksan-daeroIksan 54538Korea Department of Internal Medicine Jeonbuk National University Medical SchoolJeollabuk-doJeonju 54907Korea Division of Hematology-Oncology Department of Internal MedicineSoonchunhyang University College of MedicineBucheon HospitalWonmi-guBucheon 14584Korea Division of Hematology-Oncology Department of Internal MedicineKorea University Guro HospitalGuro-guSeoul 08308Korea Division of Hematology-Oncology Department of Internal MedicineDong-A University College of MedicineSeo-guBusan 49201Korea Department of Internal Medicine Division of Hematology-Oncology Catholic University of DaeguDaegu 42472Korea Division of Hematology-Oncology Department of Internal MedicineHallym U

Dear Editor,Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation(ASCT)and salvage therapy with bendamustine,lenalidomide or bortezomib,mantle cell lymphoma(MCL)is still considered incurable and most patients experience relapse or refractory(RR)disease.

关键词： patients relapse lymphoma

Interactions between Transmembrane Helices within Monomers of the Aquaporin AtPIP2;1 Play a Crucial Role in Tetramer Formation

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Molecular Plant 2016年第7期9卷 1004-1017页

作者： Yun-Joo Yoo Hyun Kyung Lee Wonhee Han Dae Heon kim Myoung Hui Lee Jouhyun Jeon Dong Wook Lee Junho Lee Yongjik Lee Juhun Lee jin seok kim Yunje Cho jin-Kwan Han Inhwan Hwang School of Interdisciplinary Bioscience and Bioengineering Pohang University of Science and Technology Pohang 790-784 Korea Department of Life Sciences Pohang University of Science and Technology Pohang 790-784 Korea Department of Biology Sunchon National University Sunchon 57922 Korea Division of Integrative Biosciences and Biotechnology Pohang University of Science and Technology Pohang 790-784 Korea

Aquaporin （AQP） is a water channel protein found in various subcellular membranes of both prokaryotic and eukaryotic cells. The physiological functions of AQPs have been elucidated in many organisms. However, understanding their biogenesis remains elusive, particularly regarding how they assemble into tetramers. Here, we investigated the amino acid residues involved in the tetramer formation of the Arabidopsis plasma membrane AQP AtPIP2;1 using extensive amino acid substitution mutagenesis. The mutant proteins V41A/ E44A, F51A/L52A, F87A/191A, F92A/193A, V95A/Y96A, and H216A/L217A, harboring alanine substitutions in the transmembrane （TM） helices of AtPIP2;1 polymerized into multiple oligomeric complexes with a vari- able number of subunits greater than four. Moreover, these mutant proteins failed to traffic to the plasma membrane, instead of accumulating in the endoplasmic reticulum （ER）. Structure-based modeling revealed that these residues are largely involved in interactions between TM helices within monomers. These results suggest that inter-TM interactions occurring both within and between monomers play crucial roles in tetramer formation in the AtPIP2;1 complex. Moreover, the assembly of AtPIP2;1 tetramers is critical for their trafficking from the ER to the plasma membrane, as well as water permeability.

关键词： aquaporin AtPIP2 tetramer formation interaction between transmembrane helices

采用超导故障限流器的环形供配电系统的电压骤降分析

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

智能建筑电气技术 2014年第1期8卷 104-107页

作者： Jong-Fil Moon jin-seok kim

概述在过去几十年．超导技术在各个领域的应用飞速发展。特别是超导故障电流限制器（SFCLs）已在韩国的供配电系统中得到了实际应用。超导故障电流限制器可以降低故障电流，减少对电力系统的影响，最终可以减小断路器的容量。

关键词：供配电系统超导故障限流器超导故障电流限制器电压骤降环形超导技术电力系统断路器

Phase Ⅱ study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma:consortium for improving survival of lymphoma(CISL)study

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2019年第1期39卷 526-535页

作者： Sung Yong Oh Won Seog kim jin seok kim seok jin kim Dok Hyun Yoon Deok-Hwan Yang Won Sik Lee Hyo Jung kim Ho-Young Yhim Seong Hyun Jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung-Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong-Won Lee Jae Hoon Lee Ho Sup Lee Ho-jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guSeoul 05505Republic of Korea Department of Hematology-Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology-Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology-Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology-Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology-Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

Background:The response rate and survival improvement for rituximab,a CD20-targeting monoclonal antibody,have been demonstrated in marginal zone lymphoma(MZL)as monotherapy and in combination with chemotherapeutic regimens,yet relapses still occur despite treatment ***,extending the period of remission in MZL patients remains an essential *** multicenter,single-arm,open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone).The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further ***:Prior to rituximab-maintenance therapy,patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV ***(375 mg/m^(2)),cyclophosphamide(750 mg/m^(2)),and vincristine(1.4 mg/m^(2);maximum 2 mg)were administered via an intravenous infusion on day 1 of each 3-week cycle,while oral prednisolone(100 mg)was given on days 1-5 of each 3-week *** patients who achieved complete response(CR),partial response(PR),or stable disease(SD)to R-CVP treatment,were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m^(2) every 8 weeks for up to 12 *** primary endpoint was progression-free survival(PFS).Secondary endpoints were overall survival(OS)and treatment ***:47 patients were enrolled,of whom,45(96%)received rituximab-maintenance ***(33%)patients had nodal *** R-CVP first-line therapy,20(44%),22(49%),and 3(7%)patients achieved CR,PR,and SD,*** a median follow-up of 38.2 months,their observed 3-year PFS rate was 81%.During the rituximab-maintenance,6 PR and 1 SD patients achieved CR following the administration of *** LDH and the presence of B symptoms were found to be significant prognostic fac

关键词： Marginal zone Lymphoma Advanced stage Rituximab Cyclophosphamide Vincristine Maintenance Multicenter Open label Survival

High mobility group box 1 in the central nervous system:regeneration hidden beneath inflammation

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Neural Regeneration Research 2025年第1期20卷 107-115页

作者： Hanki kim Bum Jun kim Seungyon Koh Hyo jin Cho Xuelian jin Byung Gon kim Jun Young Choi Department of Brain Science Ajou University School of MedicineSuwonSouth Korea Department of Biomedical Sciences Ajou University Graduate School of MedicineSuwonSouth Korea Department of Neurology Ajou University School of MedicineSuwonSouth Korea Department of Geriatrics The Affiliated Suqian First People’s Hospital of Nanjing Medical UniversitySuqianJiangsu ProvinceChina

High-mobility group box 1 was first discovered in the calf thymus as a DNA-binding nuclear protein and has been widely studied in diverse fields,including neurology and ***-mobility group box 1 in the extracellular space functions as a pro-inflammatory damage-associated molecular pattern,which has been proven to play an important role in a wide variety of central nervous system disorders such as ischemic stroke,Alzheimer’s disease,frontotemporal dementia,Parkinson’s disease,multiple sclerosis,epilepsy,and traumatic brain *** drugs that inhibit high-mobility group box 1 as a damage-associated molecular pattern,such as glycyrrhizin,ethyl pyruvate,and neutralizing anti-high-mobility group box 1 antibodies,are commonly used to target high-mobility group box 1 activity in central nervous system *** it is commonly known for its detrimental inflammatory effect,high-mobility group box 1 has also been shown to have beneficial pro-regenerative roles in central nervous system *** this narrative review,we provide a brief summary of the history of high-mobility group box 1 research and its characterization as a damage-associated molecular pattern,its downstream receptors,and intracellular signaling pathways,how high-mobility group box 1 exerts the repair-favoring roles in general and in the central nervous system,and clues on how to differentiate the pro-regenerative from the pro-inflammatory *** targeting high-mobility group box 1 in the central nervous system may benefit from differentiating between the two functions rather than overall suppression of high-mobility group box 1.

关键词： central nervous system damage-associated molecular pattern ethyl pyruvate glycyrhizzin high mobility group box 1 inflammation neural stem cells neurodevelopment oligodendrocyte progenitor cells redox status regeneration

边缘区淋巴瘤晚期患者R-CVP后利妥昔单抗维持治疗的Ⅱ期研究:一项改善淋巴瘤生存协会(CISL)的研究

在线全文

学校读者我要写书评

暂无评论

癌症 2020年第3期39卷 118-128页

作者： Sung Yong Oh Won Seog kim jin seok kim seok jin kim Dok Hyun Yoon Deok‑Hwan Yang Won Sik Lee Hyo Jung kim Ho‑Young Yhim Seong Hyun Jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung‑Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong‑Won Lee Jae Hoon Lee Ho Sup Lee Ho‑jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa‑guSeoul 05505Republic of Korea Department of Hematology‑Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology‑Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多... 详细信息

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多中心、单臂、开放标签的Ⅱ期研究评估了对一线R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone;利妥昔单抗、环磷酰胺、长春新碱和泼尼松龙)治疗有反应的Ⅲ–Ⅳ期CD20阳性MZL患者进行利妥昔单抗维持治疗2年的生存率。本研究旨在明确R-CVP后利妥昔单抗维持治疗的策略是否有进一步研究的价值。方法在利妥昔单抗维持治疗之前,Ⅲ–Ⅳ期MZL患者应接受6–8周期的R-CVP一线治疗。每个周期为3周,第1 d静脉输注利妥昔单抗(375 mg/m^2)、环磷酰胺(750 mg/m^2)和长春新碱(1.4 mg/m^2;最大2 mg),第1–5 d口服泼尼松龙(100 mg)。对R-CVP治疗达到完全缓解(complete response,CR)、部分缓解(part response,PR)或疾病稳定(stable response,SD)的患者进行利妥昔单抗维持治疗,每8周静脉注射利妥昔单抗375mg/m^2,直到12个周期。主要终点为无进展生存期(progression-free surviva,PFS),次要终点为总生存期(overall survival,OS)和治疗安全性。结果共纳入47例患者,其中45(96%)例接受了利妥昔单抗维持治疗。15(33%)例患者有淋巴结MZL。在进行R-CVP一线治疗后,分别有20(44%)例、22(49%)例和3(7%)例的患者达到了CR、PR和SD。中位随访38.2个月后,患者的3年PFS率为81%。在利妥昔单抗维持治疗期间,R-CVP治疗后有6例PR和1例SD患者获得CR。LDH升高和B症状是PFS的重要预后因素(P=0.003),3年OS率为90%。利妥昔单抗维持治疗的耐受性良好,常见的治疗性不良事件为感觉性神经病(18%)、肌痛(13%)、疲劳(9%)和中性粒细胞减少(9%)。结论一线R-CVP治疗后利妥昔单抗维持治疗在Ⅲ–Ⅳ期MZL患者中不仅表现出较好的PFS,而且药物毒性反应评价良好。

关键词：边缘区淋巴瘤晚期利妥昔单抗环磷酰胺长春新碱维持多中心开放标签生存

A Multi-Center International Survey Related to the Nutritional Support after Hematopoietic Stem Cell Transplantation Endorsed by the ASIA Pacific Blood and Marrow Transplantation (APBMT)

在线全文

学校读者我要写书评

暂无评论

Food and Nutrition Sciences 2012年第3期3卷 417-421页

作者： Shigeo Fuji Takehiko Mori Vincent Lee Jessica Cheng Natalie Linton Albert Lie Navin Khattry Akio Shigematsu Naoyuki Uchida Tetsuya Eto Nguyen Duy Thang Yi-Chang Liu Deok-Hwan Yang jin seok kim Joon Ho Moon Dae-Young kim Minako Iida Ritsuro Suzuki Yoshihisa Kodera Sung-Won kim Department of Hematology and Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan. Department of Hematology and Oncology Chonnam National University Hwasun Hospital Jeollanam-do Korea Department of Hematology and Oncology Hokkaido University Hospital Hokkaido Japan Department of Hematology and Oncology Kaohsiung Medical University Hospital Taiwan (China) Department of Hematology and Oncology Kyungpook National University Hospital Daegu Korea (South) Department of Hematology Asan Medical Center Seoul Korea (South) Department of Hematology Hamanomachi Hospital Fukuoka Japan Department of Hematology Toranomon Hospital Tokyo Japan Department of Hematology University Hospital Wuerzburg Wuerzburg Germany Department of HSCT Data Management and Biostatistics School of Medicine Nagoya University Nagoya Japan Department of Medical Oncology Tata Memorial Center Mumbai India Department of Medicine Queen Mary Hospital Hong Kong (China) Department of Nutrion Services St Vincent’s Hospital Sydney Sydney Australia Department of Pediatrics The Chinese University of Hong Kong Prince of Wales Hospital Hong Kong (China) Department of Promotion for Blood and Marrow Transplantation School of Medicine Aichi Medical University Nagakute Japan Division of Hematology Keio University Hos- pital Tokyo Japan Division of Hematology Yonsei University College of Medicine Severance Hospital Seoul Korea (South) Hue Regional Hematology and Blood Transfusion Center Hue Central Hospital Hue City Vietnam

Background: The nutritional support after hematopoietic stem cell transplantation (HSCT) has not been well established due to the scarcity of clinical trials. To conduct international clinical trials in Asia, we performed the questionnaire survey to investigate the current standard of nutritional support after HSCT. Method: We sent the questionnaire to the physicians nominated by the Asia Pacific Blood and Marrow Transplantation (APBMT) members of each country/ region. Result: We received 15 responses from 7 different countries/regions. The target calorie amount is 1.0 - 1.3 × basal energy expenditure (BEE) in 11 institutes when partial parenteral nutrition is used. When total parenteral nutrition (TPN) is used, the target calorie amount is 1.0 - 1.3 × BEE in 9 institutes and 1.3 - 1.5 × BEE in 4 institutes. Lipid emulsion is routinely used in 12 institutes. Multivitamins and trace elements are routinely added to TPN used in most institutes. It is still uncommon to use the immunonutrition. Blood glucose levels are routinely monitored in all institutes, but the target range varies (<110 in 2 institutes, <150 in 4 institutes, and <200 in 8 institutes). Conclusions: Basic nutritional support is similar in participating institutes. However, the target glucose level varies and the use of immunonutrition is rather rare. These points can be the theme of future clinical trials.

关键词： Stem Cell Transplantation Nutritional Support Asia Pacific Blood and Marrow Transplantation